| Date | Title | Description |
| 13.03.2023 | Intrinsic Semiconductor Technologies secures £7m investment to solve the memory bottleneck for data hungry applications | |
| 08.03.2023 | Orchard Therapeutics announces strategic financing totalling up to $188m | |
| 15.02.2023 | Girl born with MLD cured after receiving gene therapy treatment developed by Orchard Therapeutics | |
| 13.02.2023 | Freeline announces the closing of sale of its CMC-focused German subsidiary | |
| 06.02.2023 | First heart patients diagnosed using technology developed by Echopoint | |
| 02.02.2023 | World Cancer Day 2023 | |
| 02.02.2023 | World Cancer Day 2023 - Q&A with Amit Nathwani | |
| 01.02.2023 | Bloomsbury Genetic Therapies announces Orphan Drug Designations of BGT-DTDS for the treatment of Dopamine Transporter Deficiency Syndrome | |
| 20.01.2023 | Freeline publishes preclinical proof-of-concept data for FLT190, its AAV gene therapy candidate for Fabry disease, in the Nature Journal Gene Therapy | |
| 10.01.2023 | Q&A with Mark Dickinson, CEO, Intrinsic | |
| 09.01.2023 | NovalGen appoints Dr Michael Owen and Mr Scott Clarke to the Board of Directors | |
| 19.12.2022 | Achilles Therapeutics presents encouraging Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma | |
| 15.12.2022 | Vodafone Group partners with Hazy to roll out synthetic data | |
| 17.11.2022 | Apollo Therapeutics and The Institute of Cancer Research enter into collaboration for cancer drug development | |
| 07.11.2022 | Carbon Re raises £4.2m seed funding to tackle gigatonnes of emissions from the highly pollutive cement industry | |
| 03.11.2022 | NovalGen announces one oral and two poster presentations at the American Society of Haematology Annual Meeting | |
| 06.10.2022 | Bloomsbury Genetic Therapies launches with Seed financing of £5m to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases | |
| 06.10.2022 | Bloomsbury Genetic Therapies launches with Seed financing of £5 million to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases | |
| 20.09.2022 | MeiraGTx’s industry-leading gene therapy manufacturing facility in Shannon, Ireland formally introduced by Head of Irish Government | The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale gene therapy manufacturing site in Ireland. The facility is unique in its scale and integrated capabilities. The site contai... |
| 08.09.2022 | Death of Her Majesty, Queen Elizabeth II | |
| 28.07.2022 | Investor Q&A: Leigh Brody | |
| 28.07.2022 | Humanloop completes $2.6m seed funding round | |
| 27.07.2022 | Meet Sebastian Hunte, UCLTF Investor | |
| 21.07.2022 | Freeline Therapeutics could reduce bleeding risk for haemophilia patients | |
| 14.07.2022 | UCL Technology Fund Showcase 2022 | Dr Anne Lane (CEO, UCL Business and UCLTF) and Dr Andrew Elder (Partner, AlbionVC and UCLTF) welcomed guests to the Showcase, who then proceeded into the Life Science and the Physical Science auditoriums to hear from some of UCLTF’s portfol... |
| 27.06.2022 | Carbon Re and Materials Processing Institute join forces for ground-breaking use of Artificial Intelligence to decarbonise steel | Carbon Re announced on Tuesday 28th June its collaboration with the Materials Processing Institute to adapt its cutting-edge AI technology to steelmaking. Leveraging the immense potential of deep learning and reinforcement learning, Carbon ... |
| 23.06.2022 | KIT-AR announces €2m in seed stage funding round | This investment was co-led by Armilar Venture Partners and Caixa Capital Risc, with participation from RKKVC and Techtree fund (managed by Iberis Semper), including the follow-on investment from Sintef Venture V and Best Horizon. |
| 27.05.2022 | NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 | |
| 26.05.2022 | NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting | |
| 30.03.2022 | Investor Q&A: Simon Goldman | |
| 14.03.2022 | International Women's Day 2022 | |
| 02.03.2022 | Epsilogen announces completion of oversubscribed £30.75m Series B finacing | |
| 28.02.2022 | We're hurtling towards a computing impasse - the investments we make now will define our future | |
| 14.02.2022 | Bramble Energy secures £35 million to fund its game changing technology to support net zero mission | |
| 02.02.2022 | Meet Pauline Stasiak, UCLTF Investor | |
| 28.01.2022 | G-quadruplex licence showcases the UCLTF’s unique commercialisation model | |
| 19.01.2022 | Qualigen Therapeutics secures worldwide rights to G4-selective transcription inhibitors from UCL to develop as cancer therapeutics | Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, has announced the exclusive worldwide in-license of a genomic q... |
| 12.01.2022 | UCLTF's Fund Managers share their trend predictions for 2022 | |
| 11.01.2022 | The rise of deeptech investments speak to an industry brimming with possibility | |
| 01.12.2021 | Investor Q&A: Tanel Ozdemir | |
| 30.11.2021 | Quell Therapeutics raises $156 million in oversubscribed Series B financing | |
| 19.11.2021 | UCLTF Webinar: The state of early-stage Climate Tech investing | Our webinar, 'The state of early-stage Climate Tech investing' offered a fascinating insight into Climate Tech investments, startups, and Net Zero strategy. |
| 21.10.2021 | On not downclimbing: the state of the biotech market | |
| 20.10.2021 | UCLTF invests in Carbon Re, a spinout helping energy-intensive industries reach Net Zero | The £1m investment has been secured from the Clean Growth Fund, alongside UCL Technology Fund (managed by Albion VC in collaboration with UCL Business Ltd), the University of Cambridge Enterprise Fund (co-managed by Parkwalk Advisors), and ... |
| 17.08.2021 | Phasecraft improves Hamiltonian simulation algorithms for near-term quantum hardware | |
| 10.08.2021 | Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet? | |
| 03.08.2021 | David Grimm talks to Startup Dads podcast | |
| 06.07.2021 | UCLTF Showcase 2021 - The Highlights | Our 2021 UCLTF showcase saw a range of academics from our portfolio companies discuss their journeys into commercialisation, their successes so far, and their goals for the future. |
| 21.06.2021 | A Window to the Past: Is the Biotech Investment Boom Going to Last? | |
| 17.06.2021 | UCL, Imperial College London and University of Cambridge are behind innovative industry university collaboration receiving £100m funding to rapidly advance cutting-edge science | |
| 08.06.2021 | NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma | London, United Kingdom, June 9, 2021 – NovalGen Ltd (“NovalGen”), a clinical stage biopharmaceutical company developing breakthrough cancer therapies today announced that it has dosed the first patient in a Phase I/2 open-label study of a f... |
| 19.05.2021 | NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma | |
| 13.05.2021 | UCL Technology Fund secures partnership with Viralgen, leading gene therapy manufacturer | |
| 07.04.2021 | NovalGen receives CTA approval to start a Phase 1/2 first in human study | London, United Kingdom, 7 April 2021 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announced that its Clinical Trial Application (“CTA”) has been accepted by the UK Medicines and Healthca... |
| 31.03.2021 | Achilles Therapeutics Announces Pricing of Initial Public Offering | |
| 29.03.2021 | Over the Hill and (still) far away for UK biotech companies | |
| 25.03.2021 | MedNous interviews Professor Amit Nathwani | Read the article here: |
| 22.03.2021 | Intrinsic closes £1.35m seed funding round to prototype next generation memory devices | |
| 11.03.2021 | Want to build a deeptech startup? Throw out the VC playbook | Building a startup isn’t easy. Despite the vast number of business births each year, business deaths match them almost like-for-like. As VCs, we’ve seen a large number come and go, but working with deeptech founders at the very fringes and ... |
| 08.03.2021 | International Women’s Day 2021 – Meet Leigh Brody, UCLTF Investment Manager | |
| 25.02.2021 | Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies | Axovia Therapeutics, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, led by renowned researcher Professor Philip Beales, launched today after being in stealth mode for the past year. Axovia i... |
| 22.02.2021 | Why you should consider manufacturing from the start of the biotech R&D process | |
| 22.02.2021 | NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials | |
| 11.02.2021 | Quell Therapeutics Expands Series A Financing to $84 Million | |
| 08.01.2021 | UCL Technology Fund talks to the PanAngium team | - |
| 04.01.2021 | Platform technologies: going deep to go wide | University researchers developing cool new platform technologies often have a wide range of funding options available to them. But there are important differences between VC funding and other sources, whether grants from governments or char... |
| 11.12.2020 | Phasecraft announces largest seed funding round for a UK quantum computing company and new technology breakthroughs | |
| 02.12.2020 | UCL Technology Fund talks to co-founders of Echopoint about all things startups, fundraising and VC | - |
| 27.11.2020 | Third Space Learning raises £4.3m Series-A extension and announces a commercial partnership with China’s NetDragon to accelerate plans for international expansion. | |
| 18.11.2020 | Nozzle.ai raises $2.6m to accelerate adoption of AI platform with brands and sellers on Amazon | |
| 27.10.2020 | UCL Technology Fund and Orchard Therapeutics: from idea to Nasdaq IPO and beyond | - |
| 27.10.2020 | An evolution in early stage gene therapy funding models | A tsunami of curative gene therapies for rare diseases will get through pivotal trials in the coming year or two. This comes on the back of substantial venture-capital finance which has brought these programs out of gestation in academic la... |
| 23.09.2020 | We are recruiting a Life Sciences Investor for the UCL Technology Fund | |
| 07.08.2020 | Freeline Therapeutics makes its NASDAQ debut | Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. It announced the prici... |
| 04.08.2020 | Bramble energy secures significant new capital to accelerate its unique fuel cell deployment | |
| 03.08.2020 | UCL Technology Fund announces first close of £100m Fund 2 | |
| 29.07.2020 | Humanloop raises funding to teach AI to learn from humans faster | |
| 18.06.2020 | UCL engineering cancer antibody therapies for Covid-19 | A new project, led by Dr Martin Pule, Senior Lecturer in Haematology and Professor Kerry Chester, Department of Oncology, will investigate pivoting existing research used in the fight against cancer by creating a unique ‘cocktail’ of recomb... |
| 20.04.2020 | Epsilogen Announces £3m Series A2 financing and licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London | Epsilogen has also announced that it has in-licenced exclusive global rights to MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London that is the first therapeutic IgE antibody to enter clinical trials. Cancer Res... |
| 24.03.2020 | AstronauTx secures UCLTF investment for dementia therapeutics | Simon Goldman, Investment Manager for the UCL Technology Fund said: |
| 17.10.2019 | Portfolio company Astroscreen featured in the Evening Standard | Ali Tehrani, CEO of Astroscreen, says creating the tools to fight disinformation online is the new arms race. |
| 23.09.2019 | Quell Therapeutics makes FierceBiotech's 2019 Fierce 15 | Formed earlier this year, UCLTF portfolio company, Quell Thereapeutics was established with the aim of developing engineered T regulatory (Treg) cell therapies. Bringing together leaders in this field of expertise, Quell will seek to utilis... |
| 16.09.2019 | Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment | Coronary heart disease is a major cause of death worldwide and more than 7 million* people have a diagnosis in the UK alone. Narrowing arteries caused by the disease are commonly treated by the insertion of tiny tubes called stents, but the... |
| 09.09.2019 | Why we Invested in Quantum Computing start-up Phasecraft | From an investor’s perspective, the gargantuan potential of quantum computing is magnetic, but there are some very good reasons to stay away. Rigetti, the poster child of quantum startups, raised $64m in highly syndicated rounds from large ... |
| 04.09.2019 | Achilles Therapeutics raises £100m in Series B | Proceeds from this financing will deliver two human proof-of-concept studies using a unique personalised T cell therapy approach targeting clonal neoantigens in non-small cell lung cancer and melanoma. These programmes are expected to enter... |
| 04.09.2019 | Orchard Therapeutics Announces Update from POC Study of OTL-203 | MPS-I is a progressive and often life-threatening inherited lysosomal storage disorder affecting children, with the most severe form known as Hurler syndrome. Patients with MPS-I often suffer from a constellation of devastating symptoms, in... |
| 27.08.2019 | UCL’s Centre for Amyloidosis and Acute Phase Proteins published in the Journal of Medicinal Chemistry | Stabilisation of the circulating protein transthyretin is a key approach for preventing its breakdown into amyloid in genetic forms of transthyretin amyloidosis (ATTR) resulting in devastating, multi-organ failure – and also in the heart du... |
| 01.08.2019 | Funding academic innovations in advanced therapies: an interview with Simon Goldman | - |
| 20.06.2019 | 2019 Brochure | The UCL Technology Fund provides both financial and direct, hands-on support for the commercialisation of UCL’s world-class research, focusing in particular on the physical and life sciences. |
| 18.06.2019 | Andrew Elder on healthtech investing | You can listen to the full podcast here. |
| 17.06.2019 | UCL Technology Fund Showcase 2019 | We would also like to thank our wonderful guest speakers for taking the time to showcase their innovation. |
| 11.06.2019 | Hazy wins 'Best Innovation in Data Protection & Privacy' | A huge congratulations to the team at Hazy for winning the 'Best Innovation in Data Protection & Privacy' at the 2019 CogX awards. CogX is the world’s leading AI festival with over 15,000 people in attendance from the highest levels of ... |
| 29.05.2019 | Fund leads £750k investment in Phasecraft | Phasecraft, cofounded by academics at UCL and the University of Bristol, is developing software for quantum computers using some of the best talent in the sector, and aims to solve problems beyond the capacity of today’s best classical comp... |
| 20.05.2019 | UCLTF completes £1m investment into Quell Therapeutics as part of £35m Series A round | Syncona announces the foundation of Quell Therapeutics, a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed £34 million with a further £1 million being contributed by UCL Technolo... |
| 30.04.2019 | UCLTF nominated for 'Investment Unit of the Year' | The winners will be revealed at the gala dinner on May 22 as part of our GUV: Fusion conference, run jointly with the GCV Symposium, in London. Find out more about GUV, and the other nominees, on the GUV Awards 2019 page. |
| 30.04.2019 | Odin Vision scales up its cancer detection technology | The company, led by Peter Mountney and Danail Stoyanov (UCL Computer Science), is developing a revolutionary artificial intelligence (AI) system to improve early detection and diagnosis of bowel cancer. |
| 18.04.2019 | Astroscreen raises $1m to detect social media manipulation | The funding round was led by Speedinvest, UCL Technology Fund, which is managed by AlbionVC in collaboration with UCLB, Luminous Ventures, AISeed and the London Co-investment Fund. Social networks are now critical to how the public consumes... |
| 16.04.2019 | Data Supports Achievement of Proof-of-Concept Milestone for OTL-300 | Orchard Therapeutics has announced the achievement of clinical proof-of-concept based on data from the trial of OTL-300, for the treatment of transfusion-dependent beta-thalassemia (TDT). |
| 28.02.2019 | Orchard Therapeutics achieves 100% survival rate during trial treatment for ADA-SCID | ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Patients with ADA-SCID are unable to fight off and frequently succumb to complications from bacterial, viral and fungal infections. |
| 03.12.2018 | Hazy included in Forbes '15 Machine Learning Companies To Watch In Europe' | Hazy is an AI spin-out from UCL and is one of the businesses invested in by the UCL Technology Fund which is managed by Albion in collaboration with UCLB. You can find the full list of companies on the Forbes website. |